Research programme: pandemic influenza virus vaccine - FluVac

Drug Profile

Research programme: pandemic influenza virus vaccine - FluVac

Alternative Names: FluVac EU-FP6 project

Latest Information Update: 27 Jul 2010

Price : $50

At a glance

  • Originator BTG; Erasmus MC; Nobilon International; Retroscreen Virology
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 11 Nov 2009 Schering-Plough has been acquired and merged into Merck & Co
  • 10 Nov 2009 This programme is still in active development
  • 19 Nov 2007 Nobilon has been acquired by Schering-Plough
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top